No translate

Đỗ Thị Hảo; Trương Quang Bình

doi:10.58354/jvc.87.2019.1174

Home

NGHIÊN CỨU LÂM SÀNG Issue: Số 87 , 2019 TIM MẠCH DỰ PHÒNG

No translate

Published: October 15, 2026

10.58354/jvc.87.2019.1174

Abstract

No translate

Keywords

No translate

References

1. American Diabetes Association, (Jun 2012), “Standards of Medical Care in Diabete - 2012”, Diabetes Care 35(Suppl 1), p. S11 - S63.

2. Angiolillo DJ, (2009 Feb 2), “Variability in responsiveness to oral antiplatelet therapy”, Am J Cardiol, 103(3 Suppl), p. 27A-34A.

3. Crescente M, Di Castelnuovo A, Iacoviello L, de Gaetano G, C Cerletti, (2008 Jun), “PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-analysis of 19 studies comprising 3,003 patients”, Thromb Haemost, 99(6), p. 1129 - 1131.

4. Davì G, Gresele P, Violi F, Basili S, Catalano M, Giammarresi C, Volpato R, Nenci GG, Ciabattoni G,

C. Patrono, (1997), “Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease.”, Circulation, 96(1), p. 69 - 75.

5. Ertugrul DT, Tutal E, Yildiz M, Akin O, Yalçin AA, Ure OS, Yilmaz H, Yavuz B, Deveci OS, Ata N, M Küçükazman, (2010 June 1), “Aspirin Resistance Is Associated with Glycemic Control, the Dose of Aspirin, and Obesity in Type 2 Diabetes Mellitus”, The Journal of Clinical Endocrinology & Metabolism, 95(6), p. 2897 - 2900.

6. Fateh-Moghadam S, Plöckinger U, Cabeza N, Htun P, Reuter T, Ersel S, Gawaz M, Dietz R, W. Bocksch, (2005 Jun), “Prevalence of aspirin resistance in patients with type 2 diabetes”, Acta Diabetol, 42(2), p. 99 - 103.

7. Gurbel PA, et al, (2007), “Effects of Diabetes on the Prevalence of Aspirin Resistance During Low Dose Aspirin Therapy”, ACC meeting 2007, Abstract, p. 1019 - 1079.

8. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, MS; Kirkman, Association; American Diabetes, Association; American Heart, Foundation. American College of Cardiology, (2010 Jun), “Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation.”, Diabetes Care, 33(6), p. 1395-1402.

10.

9. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, Kropiwnicka A, J. Drzewoski, (2004), “Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control”, Thromb Res, 113(2), p. 101 - 113.

11.

10. “Executive Summary: Standards of Medical Care in Diabetes—2009”,(2009), Diabetes Care, 32(Supplement_1), p. S6–S12.